What question did this study set out to answer?

This study aims to evaluate the feasibility of a multi-dose Cognitive Behavioral Therapy for Insomnia (CBT-I) protocol for breast cancer survivors and to examine the associated sleep continuity outcomes and adherence over time.

May 10, 2026

0435 Feasibility of Dose-Varied CBT-I, Associated Sleep Continuity Trajectories, & Adherence in Breast Cancer Survivors

Puntos clave

This study aims to evaluate the feasibility of a multi-dose Cognitive Behavioral Therapy for Insomnia (CBT-I) protocol for breast cancer survivors and to examine the associated sleep continuity outcomes and adherence over time.
Breast cancer survivors aged 25–85 (n=28; 78.6% White) were randomized into four CBT-I dose groups (4, 8, 10, or 12 sessions).
All treatment was delivered weekly via HIPAA-compliant telehealth by a CBT-I clinician.
Primary outcomes included recruitment, retention, adherence, and exploratory outcomes of sleep latency, wake after sleep onset, and early morning awakenings.
Recruitment goals were successfully achieved with 61 participants enrolled, though about half disenrolled for various reasons.
GEE models showed significant reductions in sleep latency, wake after sleep onset, and early morning awakenings across all groups (all β_time < 0, p < .001).
There was no effect of CBT-I dosage on adherence, with all groups displaying parallel trajectories (all interaction p > .10).

Resumen

Abstract Introduction Insomnia is a common and persistent concern among breast cancer survivors, often continuing well beyond active treatment. Although Cognitive Behavioral Therapy for Insomnia (CBT-I) improves sleep continuity, the optimal dose of the intervention in oncology settings remain unclear. This study assessed the feasibility of a multi-dose CBT-I protocol and examined trajectories of sleep continuity, and adherence over the course of treatment. Methods Breast cancer survivors aged 25–85 (n=28; 78.6% White), within 6 years of completing treatment, were enrolled. Eligible participants endorsing clinically significant insomnia and fatigue (85.7% insomnia+fatigue) were randomized to one of four CBT-I dose groups (4, 8, 10, or 12 sessions). All treatment was delivered weekly via HIPAA-compliant telehealth by a CBT-I clinician. Primary outcomes included feasibility metrics: recruitment goal, n=60 0, p .001). Finally, with respect to adherence, dose did not moderate differences in groups, indicating parallel trajectories across randomized groups (all interaction p .10). Conclusion A multi-dose CBT-I protocol is feasible for breast cancer survivors. Preliminary results suggest that across all groups, participants showed statistically significant improvements in sleep continuity over time (i.e., they fell asleep faster, spent less time awake during the night, and had fewer early awakenings). However there is no effect of CBT-I dosage on adherence. Analyses are ongoing. Support (if any) 1R21CA27098701

Preguntar a la IA

Me gusta

Guardar